406 related articles for article (PubMed ID: 25578944)
1. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.
Belvederi Murri M; Guaglianone A; Bugliani M; Calcagno P; Respino M; Serafini G; Innamorati M; Pompili M; Amore M
Drugs R D; 2015 Mar; 15(1):45-62. PubMed ID: 25578944
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan.
Misawa F; Okumura Y; Takeuchi Y; Fujii Y; Takeuchi H
Schizophr Res; 2021 May; 231():42-46. PubMed ID: 33752105
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports.
Guinart D; Misawa F; Rubio JM; Pereira J; Sharma H; Schoretsanitis G; Kane JM; Correll CU
J Clin Psychiatry; 2020 Nov; 82(1):. PubMed ID: 33238083
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study.
Lao KSJ; Zhao J; Blais JE; Lam L; Wong ICK; Besag FMC; Chang WC; Castle DJ; Chan EW
CNS Drugs; 2020 Nov; 34(11):1165-1175. PubMed ID: 33010024
[TBL] [Abstract][Full Text] [Related]
5. What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review.
Virolle J; Redon M; Montastruc F; Taïb S; Revet A; Zivkovic V; Da Costa J; Very E
Schizophr Res; 2023 Dec; 262():184-200. PubMed ID: 37599139
[TBL] [Abstract][Full Text] [Related]
6. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
Khaldi S; Kornreich C; Choubani Z; Gourevitch R
Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.
Trollor JN; Chen X; Sachdev PS
CNS Drugs; 2009; 23(6):477-92. PubMed ID: 19480467
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Croarkin PE; Emslie GJ; Mayes TL
J Clin Psychiatry; 2008 Jul; 69(7):1157-65. PubMed ID: 18572981
[TBL] [Abstract][Full Text] [Related]
9. Clozapine Rechallenge Following Neuroleptic Malignant Syndrome: A Systematic Review.
Lally J; McCaffrey C; OʼMurchu C; Krivoy A; Guerandel A; MacCabe JH; Gaughran F
J Clin Psychopharmacol; 2019; 39(4):372-379. PubMed ID: 31205196
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome.
Guinart D; Misawa F; Rubio JM; Pereira J; de Filippis R; Gastaldon C; Kane JM; Correll CU
Acta Psychiatr Scand; 2021 Oct; 144(4):329-341. PubMed ID: 34358327
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics.
Trollor JN; Chen X; Chitty K; Sachdev PS
Br J Psychiatry; 2012 Jul; 201(1):52-6. PubMed ID: 22626633
[TBL] [Abstract][Full Text] [Related]
13. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.
Schneider M; Regente J; Greiner T; Lensky S; Bleich S; Toto S; Grohmann R; Stübner S; Heinze M
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):23-33. PubMed ID: 30506147
[TBL] [Abstract][Full Text] [Related]
14. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature.
Karagianis JL; Phillips LC; Hogan KP; LeDrew KK
Ann Pharmacother; 1999 May; 33(5):623-30. PubMed ID: 10369628
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic malignant syndrome induced by atypical antipsychotics.
Farver DK
Expert Opin Drug Saf; 2003 Jan; 2(1):21-35. PubMed ID: 12904122
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride and neuroleptic malignant syndrome.
Tu MC; Hsiao CC
Chang Gung Med J; 2011; 34(5):536-40. PubMed ID: 22035899
[TBL] [Abstract][Full Text] [Related]
17. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome.
Stevens DL
Ann Pharmacother; 2008 Sep; 42(9):1290-7. PubMed ID: 18628446
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study.
Nielsen RE; Wallenstein Jensen SO; Nielsen J
Can J Psychiatry; 2012 Aug; 57(8):512-8. PubMed ID: 22854034
[TBL] [Abstract][Full Text] [Related]
19. Risperidone versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
[TBL] [Abstract][Full Text] [Related]
20. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?
Odagaki Y
Curr Drug Saf; 2009 Jan; 4(1):84-93. PubMed ID: 19149529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
